Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
Fu-Chih HsiaoChun-Li WangPo-Cheng ChangYu-Ying LuChien-Ying HuangPao-Hsien ChuPublished in: Journal of cardiovascular pharmacology and therapeutics (2019)
In our study, patients with HFrEF had higher BNP and serum creatinine level at baseline and had received lower dose of ARNI than the PARADIGM-HF populations. Angiotensin receptor neprilysin inhibitor appeared to be safe as regard renal function and effective in real-world practice. Left ventricular reverse remodeling was observed 1 year after heart failure medication treatment, including ARNI.
Keyphrases
- heart failure
- left ventricular
- angiotensin ii
- angiotensin converting enzyme
- healthcare
- cardiac resynchronization therapy
- primary care
- acute myocardial infarction
- acute heart failure
- hypertrophic cardiomyopathy
- metabolic syndrome
- binding protein
- atrial fibrillation
- mitral valve
- emergency department
- coronary artery disease
- replacement therapy
- acute coronary syndrome